CSE1L Links cAMP/PKA and Ras/ERK pathways and regulates the expressions and phosphorylations of ERK1/2, CREB, and MITF in melanoma cells
- PMID: 26331446
- DOI: 10.1002/mc.22407
CSE1L Links cAMP/PKA and Ras/ERK pathways and regulates the expressions and phosphorylations of ERK1/2, CREB, and MITF in melanoma cells
Abstract
The Ras/ERK (extracellular signal-regulated protein kinase) and cAMP/PKA (protein kinase A) pathways are essential for the transcriptional activities of CREB (cAMP response element binding protein) and MITF (microphthalmia-associated transcription factor) in melanogenesis and the progression of melanoma. However, the interaction between Ras/ERK and cAMP/PKA pathways in the melanogenesis and progression of melanoma is not fully known. Here, we report that CSE1L (chromosome segregation 1-like protein) regulates cAMP/PKA-induced CREB and MITF expressions as well as Ras-induced ERK1/2 phosphorylation. IBMX, a cAMP/PKA activator, treatment induced CSE1L phosphorylation and augmented Ras-induced ERK1/2 phosphorylation. CSE1L knockdown by CSE1L shRNA expression vectors inhibited Ras-induced ERK1/2 phosphorylation and melanogenesis in melanoma cells. CSE1L overexpression increased phospho-CREB expression; CSE1L knockdown also inhibited Ras-induced phospho-CREB, MITF, and tyrosinase expressions, regardless of the presence of IBMX. This study identifies CSE1L links and controls the Ras/ERK and cAMP/PKA pathways in the melanogenesis of melanoma cells. Melanomas frequently develop drug resistance via paradoxical activation of Ras/Raf/MEK/ERK or alternatively activated Ras/ERK and cAMP/PKA pathways. Thus CSE1L may be a potential target for treating melanomas that harbor Ras mutations or are resistant to drugs targeting Raf/MEK/ERK. © 2015 Wiley Periodicals, Inc.
Keywords: CREB; CSE1L; ERK1/2; MITF; Ras; melanoma.
© 2015 Wiley Periodicals, Inc.
Similar articles
-
CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy.Tumour Biol. 2016 Oct;37(10):13077-13090. doi: 10.1007/s13277-016-5301-x. Epub 2016 Sep 5. Tumour Biol. 2016. PMID: 27596143 Review.
-
High expression of cytoplasmic phosphorylated CSE1L in malignant melanoma but not in benign nevi: phosphorylated CSE1L for the discrimination between melanoma and benign nevi.Int J Clin Exp Pathol. 2015 Feb 1;8(2):1393-401. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 25973023 Free PMC article.
-
CSE1L silence inhibits the growth and metastasis in gastric cancer by repressing GPNMB via positively regulating transcription factor MITF.J Cell Physiol. 2020 Mar;235(3):2071-2079. doi: 10.1002/jcp.29107. Epub 2019 Jul 25. J Cell Physiol. 2020. PMID: 31347172
-
Inhibition of Mek 1/2 kinase activity and stimulation of melanogenesis by 5,7-dimethoxycoumarin treatment of melanoma cells.Int J Oncol. 2009 Jun;34(6):1727-35. doi: 10.3892/ijo_00000303. Int J Oncol. 2009. PMID: 19424591
-
Epigenetic regulation in human melanoma: past and future.Epigenetics. 2015;10(2):103-21. doi: 10.1080/15592294.2014.1003746. Epigenetics. 2015. PMID: 25587943 Free PMC article. Review.
Cited by
-
Cellular apoptosis susceptibility protein (CAS) suppresses the proliferation of breast cancer cells by upregulated cyp24a1.Med Oncol. 2020 Apr 8;37(5):43. doi: 10.1007/s12032-020-01366-w. Med Oncol. 2020. PMID: 32270348
-
Targeting CREB in Cancer Therapy: A Key Candidate or One of Many? An Update.Cancers (Basel). 2020 Oct 28;12(11):3166. doi: 10.3390/cancers12113166. Cancers (Basel). 2020. PMID: 33126560 Free PMC article. Review.
-
Identification of SNPs in MITF associated with beak color of duck.Front Genet. 2023 Aug 21;14:1161396. doi: 10.3389/fgene.2023.1161396. eCollection 2023. Front Genet. 2023. PMID: 37671042 Free PMC article.
-
Nuclear export protein CSE1L interacts with P65 and promotes NSCLC growth via NF-κB/MAPK pathway.Mol Ther Oncolytics. 2021 Mar 10;21:23-36. doi: 10.1016/j.omto.2021.02.015. eCollection 2021 Jun 25. Mol Ther Oncolytics. 2021. PMID: 33869740 Free PMC article.
-
Integrated transcriptome analysis of CSE1L regarding poor prognosis and immune infiltration in bladder urothelial carcinoma and experimental verification.Front Immunol. 2024 Oct 4;15:1449251. doi: 10.3389/fimmu.2024.1449251. eCollection 2024. Front Immunol. 2024. PMID: 39430746 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous